(MedPage Today) -- The mortality reduction seen in acute heart failure with the blood vessel relaxer serelaxin may be a real effect from reduced end-organ damage and faster decongestion, exploratory analysis of the RELAX-HF trial data suggested. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment